Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

HANCOCK JAFFE LABORATORIES, INC.

(HJLI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hancock Jaffe Laboratories Gets Breakthrough Device Designation for VenoValve

08/03/2021 | 06:46am EDT

By Chris Wack

Hancock Jaffe Laboratories Inc. said the U.S. Food and Drug Administration has granted breakthrough device designation status to VenoValve, its lead product, which is set to begin its U.S. pivotal trial.

The FDA's breakthrough devices program was established to enable priority review for devices that provide more effective treatment or diagnosis of life threatening or irreversibly debilitating diseases or conditions.

The medical device company said VenoValve is a potential treatment for chronic venous insufficiency, which occurs when valves inside of the veins of the leg fail, causing blood to flow in the wrong direction and creating increased pressure inside of the veins of the leg.

The primary endpoint for the new U.S. trial will be the occurrence of material adverse effects in less than 10% of patients at 30 days post-VenoValve implantation, and the primary effectiveness endpoint is improvement of reflux equal to or greater than 30% at six months following VenoValve surgery.

Hancock Jaffe shares were up 37% to $9 in premarket trading.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

08-03-21 0846ET

All news about HANCOCK JAFFE LABORATORIES, INC.
09:12aHANCOCK JAFFE LABORATORIES : to Participate in the Duologue Series Virtual Webinar Hosted ..
PU
09/22HANCOCK JAFFE LABORATORIES : Announces Corporate Rebranding to Reflect Prioritization of i..
PU
09/22HANCOCK JAFFE LABORATORIES, INC. : Other Events, Financial Statements and Exhibits (form 8..
AQ
09/22Hancock Jaffe Laboratories, Inc Begins Enrollment for the U.S. Pivotal Trial for the Ve..
CI
09/21HANCOCK JAFFE LABORATORIES : Will Change Name to enVVeno Medical in October
MT
09/21HANCOCK JAFFE LABORATORIES : Announces Corporate Rebranding to Reflect Prioritization of i..
PU
09/15HANCOCK JAFFE LABORATORIES : to Host Corporate Update Conference Call and Webcast on Septe..
PU
09/08HANCOCK JAFFE LABORATORIES, INC. : Entry into a Material Definitive Agreement, Financial S..
AQ
09/07HANCOCK JAFFE LABORATORIES : Launches $20 Million Registered Direct Offering
MT
09/07HANCOCK JAFFE LABORATORIES : Announces $20 Million Registered Direct Offering Priced At-th..
PU
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -12,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -7,06x
Yield 2021 -
Capitalization 84,0 M 84,0 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 19
Free-Float 90,4%
Chart HANCOCK JAFFE LABORATORIES, INC.
Duration : Period :
Hancock Jaffe Laboratories, Inc. Technical Analysis Chart | HJLI | US41015N3044 | MarketScreener
Technical analysis trends HANCOCK JAFFE LABORATORIES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 9,67 $
Average target price 26,00 $
Spread / Average Target 169%
EPS Revisions
Managers and Directors
Robert Andrew Berman Chief Executive Officer & Director
Craig T. Glynn Chief Financial Officer & Treasurer
Marc H. Glickman Chief Medical Officer & Senior Vice President
Hamed Alavi Vice President-Research, Development & Quality
Francis Duhay Independent Director
Sector and Competitors
1st jan.Capi. (M$)
HANCOCK JAFFE LABORATORIES, INC.11.79%84
MASIMO CORPORATION6.11%15 679
NOVOCURE LIMITED-24.30%13 547
GETINGE AB100.52%12 150
PENUMBRA, INC.61.48%10 337
ASAHI INTECC CO., LTD.-12.08%8 012